Compare ARAY & BCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARAY | BCTX |
|---|---|---|
| Founded | 1990 | 2014 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.3M | 36.6M |
| IPO Year | 2006 | 2025 |
| Metric | ARAY | BCTX |
|---|---|---|
| Price | $0.30 | $4.18 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 11.5M | 149.6K |
| Earning Date | 11-04-2026 | 10-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 87.50 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2.75 | N/A |
| Revenue Next Year | $2.35 | $380.95 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.22 | $2.60 |
| 52 Week High | $2.10 | $14.68 |
| Indicator | ARAY | BCTX |
|---|---|---|
| Relative Strength Index (RSI) | 61.57 | 56.58 |
| Support Level | $0.24 | $4.10 |
| Resistance Level | $0.34 | $4.49 |
| Average True Range (ATR) | 0.03 | 0.30 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 52.97 | 70.00 |
Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise, treatment solutions which set the standard of radiation therapy care with the objective of helping patients live lives. The company's technology, The CyberKnife, is used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for a tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimetre accuracy while patients breathe normally, without manual user intervention. The company has one operating segment which develops, manufactures and markets proprietary medical devices used in radiation therapy for the treatment of cancer patients.
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.